RÉSUMÉ
Relapsing polychondritis (RP) is a systemic immune mediated disease characterized by recurrent episodes of inflammation in various cartilage-rich areas. RP may cause extensive tissue destruction and is associated with significant morbidity and mortality. In this multicenter study, we considered the remission status and long-term outcomes of RP in patients who were followed-up in six referral rheumatology centers in Iran. Outcomes of disease was assessed by remission status and RP induced damage. A total of 29 patients with RP were examined for enrollment in the study, and 26 patients with a minimum follow-up period of 6 months were included in the RP outcome analysis. Median time to control of symptoms and sustained remission were 5 and 23 weeks, respectively. Prednisolone was discontinued in 8 (30.8%) patients and medication-free remission was achieved in 7 (23.1%) patients. Regarding the disease course, 34.6% of patients had a relapsing-remitting course, 42.3% had a monophasic course, and 23.1% had an always-active course. Despite extensive treatment with immunosuppressive medications, RP induced damage was developed in 21 (80.8%) patients. Ear deformity and osteoporosis were the most common RP induced damage. Long-term remission and medications-free remission in RP is accessible. However, RP related damage occur in majority of patients.
Sujet(s)
Polychondrite chronique atrophiante , Humains , Polychondrite chronique atrophiante/traitement médicamenteux , Polychondrite chronique atrophiante/complications , Mâle , Femelle , Iran/épidémiologie , Adulte , Adulte d'âge moyen , Résultat thérapeutique , Induction de rémission , Prednisolone/usage thérapeutique , Sujet âgé , Immunosuppresseurs/usage thérapeutique , Jeune adulte , Études de suiviRÉSUMÉ
BACKGROUND: Behcet's disease (BD) as a chronic inflammatory condition that affects the eyes, skin, central nervous system, gastrointestinal tract and vessels. According to the literature, the exact value of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in predicting active manifestations of BD remains controversial. In this study, we aim to assess and compare values of ESR and CRP between BD patients with active/inactive BD and active/inactive manifestations of the disease. Moreover, we try to determine the predictive value of ESR and CRP for disease activity. METHODS: Participants (n = 514) were drug-naïve BD patients; Based on last two visits, ESR and CRP values, disease activity, and active manifestations were recorded. The Man-Whitney U test measured the associations, and the binomial logistic regression evaluated the predictive value of ESR and CRP for active disease and each active manifestation. The sensitivity and specificity and the area under the curve (AUC) for each model were determined using receiver operating characteristic curves (ROC). Multiple regressions were run to predict BD activity score from ESR and CRP. RESULT: Patients with active oral, genital, joint and dermal manifestations had higher ESR and CRP values (Mann-Whitney U test, p < 0.05 for all). Binomial logistic regressions showed that ESR had valuable predictive value for active BD (OR = 1.09 [1.04-1.13], AUC = 0.79 [0.74-0.83], p < 0.001) and active vascular manifestations (1.03 [1.01-1.05], AUC = 0.85 [0.79-0.92], p < 0.001). CRP had good predictive value for active vascular manifestations (OR 1.98 [1.45-2.72], AUC = 0.86 [0.8-0.91], p < 0.001). The optimal value of ESR ≥ 10.5 and ESR ≥ 42.5 could predict active BD and active vascular manifestations with sensitivity, specificity = 71%, 75% and = 81%, 83% respectively. CONCLUSIONS: ESR and CRP are both associated with active BD and most manifestations of the diseases. They can be used for the prediction of active BD and active vascular manifestations in BD patients. Further studies can help to confirm the findings of the current research.
RÉSUMÉ
BACKGROUND: A strong correlation was previously found between mean platelet volume (MPV), red blood cell distribution width (RDW), and the severity of signs and symptoms in patients suffering from inflammatory and autoimmune diseases. The current study evaluated these correlations in patients with Behçet's disease (BD) as well the relationship between MPV and RDW and disease activity score on the Iranian Behçet's Disease Dynamic Activity Measurement (IBDDAM). METHODS: This cross-sectional study included 319 patients with BD for whom demographic and epidemiological data, IBDDAM scores, and duration of illness was recorded. Blood samples were then obtained and the relationships between their disease status and manifestations and their laboratory parameters were evaluated with statistical models to find possible correlations. RESULTS: Our analysis showed a significantly higher RDW in patients with BD who had ocular manifestations (p < 0.001) and oral aphthae (p = 0.004). Patients with active BD had higher RDW (p < 0.001) and MPV (p < 0.001) in comparison to those with currently inactive BD. Similarly, patients who had any type of ocular manifestation had higher RDW (p < 0.001) and MPV (p < 0.001). Regression analyses identified a statistically significant model for the effect of RDW and MPV in predicting active BD status (p < 0.001), as well as its significant relationship with active ocular manifestations (p < 0.001). CONCLUSION: BD was found to be associated with an increase in MPV and RDW, particularly during active phases. RDW and MPV were also found to have predictive value for screening to detect BD activity and its ocular complications.
Sujet(s)
Maladie de Behçet , Volume plaquettaire moyen , Études transversales , Index érythrocytaires , Humains , IranRÉSUMÉ
OBJECTIVE: Behcet's disease (BD), as a vasculitis, can affect small and large vessels. As dermatoscopy has been shown to improve the accuracy in diagnosis of various skin lesions especially vascular patterns, we set this study to find if there is any characteristic pattern in the dermatoscopy of Behcet's mucocutaneous lesions. METHODS: This prospective cross-sectional observational study designed to evaluate dermatoscopic features of Behcet's mucocutaneous lesions. Fifty six consecutive patients presenting at the outpatient clinic of the BD Research Unit were included. If present, for each patient one oral, one skin and one genital lesion were evaluated by dermatoscopy. When indicated, pathergy test was performed according to a standard protocol and the results were evaluated by dermatoscopy. RESULTS: A total of 40 oral, 8 genital, 14 skin lesions and 14 pathergy tests were evaluated by dermatoscopy. While vascular component was the most prominent feature in oral aphthae, this component was less prominent in genital lesions. Dot vessels were the most common form of vessels in both oral and skin lesions. All the oral lesions were characterized by a central white structureless area. Skin lesions were characterized by a red structureless background. In pathergy tests, negative pricks showed absence of specific features while positive pricks were characterized by a structureless background in pink, purple or red. No obvious vascular component was detected in any of the pricks. CONCLUSION: It seems that these findings have no specific clues for the diagnosis of BD, but our study is the first study in this field and the findings may give way to further investigations.
Sujet(s)
Maladie de Behçet/anatomopathologie , Dermoscopie , Muqueuse/anatomopathologie , Peau/anatomopathologie , Adulte , Études transversales , Femelle , Humains , Mâle , Adulte d'âge moyen , Études prospectivesRÉSUMÉ
Objective: To analyze Behcet's Disease (BD) in Iran, from 1975 to 2018, and compare to 35 large/small reports from other countries.Methods: Patients from all over Iran, when suspected, were sent to the BD Unit. The diagnosis was done by expert opinion. All data were recorded in the BD registry (updated in each follow-up). The data are given in percentage with 95% confidence Intervals.Results: The mean age at onset was 25.6 years. Standard deviation (SD) was 9.8. The mean disease duration was 11.7 years (SD: 8.9). Males were 55.8% (54.7-56.9), Females 44.2% (43.1-45.3), Oral Aphthosis (OA) 97.5% (97.1-97.9), genital aphthosis (GA) 64.4% (63.3-65.5), skin lesions 62.2% (61.1-63.3), ocular lesions 55.6% (54.5-56.7), Joint Manifestations 38.1% (37.0-39.2), Gastrointestinal 6.8% (6.2-7.4), Vascular 8.9% (8.3-9.5), neurological (central-peripheral) 3.9% (3.5-4.3), epididymitis 4.6% (4.1-5.1). Lab tests were positive pathergy test 50.4% (49.3-51.5), elevated ESR 51.1% (50.0-52.2), abnormal urinalysis 13.4% (12.6-14.2). The International Study Group (ISG, 1990) criteria and the International Criteria for Behcet's Disease (ICBD, 2014) had respectively a sensitivity of 76.2% (75.2-77.2) and 96.6% (96.2-97.0). The specificity was 99.3% (99.1-99.5) and 97.3% (96.9-97.7). The accuracy was 86.4% (85.8-87.0) and 96.9% (96.6-97.2).Conclusion: The most frequent manifestations were OA, GA, skin manifestations, and ocular manifestations.
Sujet(s)
Maladie de Behçet/épidémiologie , Enregistrements , Adolescent , Adulte , Âge de début , Maladie de Behçet/classification , Maladie de Behçet/anatomopathologie , Femelle , Humains , Iran , Mâle , Adulte d'âge moyenRÉSUMÉ
INTRODUCTION: This is an analysis of adult Behcet's disease (BD) in Iran, from the Iran Registry of 7187 BD patients, gathered from 1975 to 2014, among which 6075 were adults (84.5%). PATIENTS: Patients were seen by a multidisciplinary team of experts. The diagnosis was by expert opinion, not by any specific classification/diagnosis criteria. However, 96.8% of them were classified by the International Criteria for Behcet's Disease (ICBD). Adult BDs were patients who had their first manifestation at the age of 16 or later. RESULTS: Males constituted 56% (male/female ratio 1.3/1). The mean age at onset was 28.3 ± 8.7, mean duration 10.8 ± 8.2, and mean follow-up 5.0 ± 6.3. Oral aphthosis was seen in 97.5%, genital aphthosis 65.7%, skin manifestations 64.6% (pseudofolliculitis 53.2%, erythema nodosum 23.9%), ocular manifestations 58.1% (anterior uveitis 41.1%, posterior uveitis 45%, retinal vasculitis 33.6%, cataract 24.4%), joint manifestations 39.4% (arthralgia 18.9%, monoarthritis 9.1%, oligoarthritis 17.8%, ankyloing spondylitis 2%), gastrointestinal manifestations 7% (gastroduodenitis 2.3%, peptic ulcer 1.2%, diarrhea 2.1%, rectorrhagia 1.0%, abdominal pain-nausea 1.8%), neurological manifestations 10.6% (central 3.7%, peripheral 0.3%, headache 7.6%), vessel involvement (large vessel 1.7% with large vein thrombosis 1.1% and arterial involvement 0.7%, phlebitis 6.6%, superficial phlebitis 2.3%), epididymitis 4.6%, pulmonary manifestations 1% and cardiac manifestations 0.6%. Positive pathergy test was seen in 52.3%, human leukocyte antigen (HLA)-B5 in 54%, HLA-B51 in 48.9%, and high erythrocyte sedimentation rate in 52.8% of patients. By International Study Group (ISG) criteria 77.9% were classified, compared to ICBD revised criteria with 96.9%. The specificity of ISG was 99.2% and ICBD 97.2%. CONCLUSION: Results are near the nationwide surveys from Japan, China, Korea and Germany.
Sujet(s)
Maladie de Behçet/épidémiologie , Adolescent , Adulte , Facteurs âges , Maladie de Behçet/diagnostic , Évolution de la maladie , Femelle , Humains , Iran/épidémiologie , Mâle , Valeur prédictive des tests , Pronostic , Enregistrements , Facteurs de risque , Facteurs sexuels , Facteurs temps , Jeune adulteRÉSUMÉ
The aim of this study was to evaluate the psychometric properties of tools "Team-Based Learning Student Assessment Tool", Classroom Engagement Survey (CES) and to assess the reaction of learners toward TBL sessions at Tehran University of Medical Sciences. This descriptive study was done in 2013. The first step was to assess the reliability and validity of the tools. TBL-SAI questionnaire include 39 items, and CES consists 8 items. The validity was assessed through Delphi rounds by experts and reliability, through internal consistency and Test-Retest approach. Then, the reaction of medical students (N=78) was assessed concerning the aspects of team-based learning sessions through TBL-SAI and CES. The data were analyzed through descriptive tests. Our results have study confirmed the TBL-SAI and CEA validity. The tools 'reliability was approved through: TBL-SAI Cronbach's alpha=0.79, CES Cronbach's alpha=0.71 and TBL-SAI ICC=0.82, CES ICC=0.75. The result of the second phase showed the TBL_SAI scores of participation were appropriate concerning TBL session (12.89±159.60). According to confirmed validity of tools, these can be used in researches related to team-based learning in Iran. It could facilitate assessing the learners' reaction of team-based learning studies at Iranian medical science universities. In the present study, the reaction of students who participate in TBL sessions had been positive and their participation, satisfaction, and accountability had been improved.
Sujet(s)
Évaluation des acquis scolaires/méthodes , Processus de groupe , Apprentissage par problèmes/méthodes , Étudiant médecine/psychologie , Adulte , Femelle , Humains , Iran , Apprentissage , Mâle , Satisfaction personnelle , Reproductibilité des résultats , Enquêtes et questionnairesRÉSUMÉ
There are 17 sets of diagnosis/classification criteria for Behcet's disease: Curth (1946), Hewitt (1969), Mason (1971), Japan (1972), Hubault (1974), O'Duffy (1974), Cheng (1980), Dilsen (1986), Japan revised criteria (1988), International Study Group on Behcet's disease (ISG criteria, 1990), Iran traditional criteria (1993), Iran Classification Tree (1993), Dilsen revised criteria (2000), Korea Criteria (2003), International Criteria for Behcet's Disease (ICBD, 2006) and the revised ICBD (2010). This review is intended to show how to use them and show their performance in patients from different parts of the world. The major sets of patients (patient numbers, control numbers, year) on which the criteria were tested are: ISG set (886/97/1990), Iran (2069/1540/1993), Asia and Pacific League of Associations for Rheumatology (APLAR: 216/145/1998), Russia (105/233/2000), USA (50/NA/2000 [NA: not available]), India (50/NA/2004), Singapore (37/NA/2004), China (98/NA/2004), Korea (1454/NA/2004), Iran (4900/2020/2004), ICBD (2556/1163/2006), Germany (86/38/2008), China (322/118/2008), Iran (6128/3400/2010) and Iran (7011/5226/2013). For the following criteria sets (O'Duffy, Dilsen, Japan revised, ISG, Korea, ICBD, revised ICBD), the sensitivity in ISG cohort was 82/95/93/91/NA/NA/NA%, in APLAR 62.5/75/73/72/NA/NA/NA%, in Russia 91/92/92/86/NA/NA/NA%, USA 88/85/82/76/NA/NA/NA%, ICBD 83/87/88/82/90/96/96%, China 64/71/66/65/85/87/NA% and in Iran (2013) 69.5/81/86/77.5/86/98/97%. Specificity in ISG was 83/79/89/96/NA/NA/NA%, in APLAR 98/96/99/99/NA/NA/NA%, in Russia 88/91/92/100/NA/NA/NA%, ICBD 95/91/92/96/93/89/91%, China 97.5/95/98/99/97/94/NA% and in Iran (2013) 99/95/98/99/98/96/97%. Accuracy in ISG was 82.5/87/91/93.5/NA/NA/NA%, in APLAR 80/85/86/86/NA/NA/NA%, in Russia 89.5/92/92/93/NA/NA/NA%, ICBD 87/88/89/87/91/94/94.5%, China 72/78/74/74/88/89/NA% and in Iran (2013) 82/87/91/87/91/97/97%. ISG criteria has very good specificity, but lacks good sensitivity and accuracy. In contrast, ICBD has much better sensitivity, a little less specificity and better accuracy.
Sujet(s)
Maladie de Behçet/diagnostic , Indicateurs d'état de santé , État de santé , Maladie de Behçet/classification , Maladie de Behçet/épidémiologie , Humains , Valeur prédictive des tests , Pronostic , Reproductibilité des résultats , Terminologie comme sujetRÉSUMÉ
The first internationally agreed criteria for Behcet's disease were the International Study Group (ISG) criteria. It had very high specificity, but lacked good sensitivity, missing an important subset of patients. The International Criteria for Behcet's Disease (ICBD) were created in 2006 to overcome this lack of sensitivity. It was revised in 2010. The objective of this study was to evaluate the performance of the revised International Criteria for Behcet's Disease (rICBD) in Iran. In this study, the ISG and ICBD were evaluated and compared to the rICBD. All patients from the Behcet's Disease Registry (7,011) and controls (5,226), up to March 2013, entered the study. The diagnosis was clinical, by expert opinion. Sensitivity, specificity, and accuracy were calculated for ISG, ICBD, and rICBD. A 95% confidence interval (95%CI) was calculated for percentages. For ISG, the sensitivity was 77.5% (95%CI = 76.5-78.5). It was 98.3% for ICBD (95%CI = 98.0-98.6) and 96.8% for rICBD (95%CI = 96.4-97.2). Specificity was 99.2% (95%CI = 99.0-99.4) for ISG, 96.2% for ICBD (95%CI = 95.7-96.7), and 97.2% for rICBD (95%CI = 96.8-97.6). Accuracy was 86.7% (95%CI = 86.1-87.3) for ISG, 97.4% for ICBD (95%CI = 97.1-97.7), and 97.0% for rICBD (95%CI = 96.7-97.3). In Iranian patients, ICBD has 20.8% and rICBD 19.3% higher sensitivity than ISG. Although the specificity was lower than ISG by 3% for ICBD and 2% for rICBD, the accuracy was higher respectively by 10.7 and 10.3%. ICBD has by far better performance than ISG. The difference was even more prominent in Iranian patients than for the ICBD cohort of patients and controls.
Sujet(s)
Maladie de Behçet/diagnostic , Adolescent , Adulte , Sujet âgé , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Nourrisson , Iran , Mâle , Adulte d'âge moyen , Enregistrements , Sensibilité et spécificité , Jeune adulteRÉSUMÉ
AIM: To estimate the prevalence of osteoarthritis (OA) of different joints in rural areas of Iran. METHODS: From five villages of Tuyserkan County, 1565 individuals were randomly selected and were interviewed to complete the Community Oriented Programme for Control of the Rheumatic Diseases (COPCORD) Core Questionnaire. Among these cases 1192 cases with rheumatic complaints were examined by a rheumatologist and laboratory and radiology tests were performed if necessary for the diagnosis. Definition of OA in various joints, were based on American College of Rheumatology (ACR) criteria. RESULTS: About 20% of the study population had OA in at least one of their joints. Prevalence of OA in the knee joint was 19.34%, in hand joins was 2.66% and in the neck was 2.21%. The most common findings on physical examination of patients with knee OA, hand OA and neck OA were bony crepitus (88.9%), Heberden's nodes (73.2%) and pain on movement (59.9%), respectively. CONCLUSIONS: This study revealed that OA in rural areas of Iran was more frequent in comparison with urban areas of Iran. Moreover, the prevalence of OA in rural areas of Iran was higher in comparison with prevalence of OA in rural areas of other Asian countries. Similar to previous studies OA was more frequently detected in the knee joint.
Sujet(s)
Articulations , Arthrose/épidémiologie , Santé en zone rurale , Adolescent , Adulte , Sujet âgé , Arthrographie , Femelle , Humains , Iran/épidémiologie , Articulations/anatomopathologie , Articulations/physiopathologie , Mâle , Adulte d'âge moyen , Arthrose/diagnostic , Arthrose/physiopathologie , Examen physique , Prévalence , Jeune adulteRÉSUMÉ
AIM: Ocular lesions of Behcet's disease (BD) need aggressive treatment to prevent severe loss of vision or blindness. Cytotoxic drugs are the main therapeutic agents and the first line treatment. Retinal vasculitis is the most aggressive lesion of ocular manifestations and predicts a worse systemic outcome. We present here the outcome with a combination of pulse cyclophosphamide, azathioprine and prednisolone, on long-term usage, up to 10 years, on 295 patients (18 493 eye-months of follow-up). METHODS: Cyclophosphamide was used as a 1-g monthly pulse for 6 months and then every 2-3 months as necessary. Azathioprine was used at 2-3 mg/kg daily. Prednisolone was initiated at 0.5 mg/kg daily. Upon the suppression of the inflammatory reaction, prednisolone was tapered gradually. Patients fulfilled the International Criteria Behcet's Disease (ICBD) and had active posterior uveitis (PU) and/or retinal vasculitis (RV). Visual acuity (VA), PU, RV and TADAI (Total Adjusted Disease Activity Index) were calculated. RESULTS: Overall results: mean VA improved from 3.5 to 4.3 (P < 0.0001), 44% of eyes improved (95% CI = 40-50). Mean PU improved from 2.1 to 0.8 (P < 0.0001), 73% of eyes improved (95% CI = 69-78). Mean RV improved from 3.0 to 1.4 P < 0.0001), 70% of eyes improved (95% CI = 65-74). Mean TADAI improved from 29 to 18 (P < 0.0001), 72% of patients improved (95% CI = 66-77). The details of the longitudinal studies are given in the main article. CONCLUSION: All parameters significantly improved. VA improvement was the least, mainly due to cataracts. This combination is the best treatment choice for retinal vasculitis before opting for biologic agents.
Sujet(s)
Azathioprine/administration et posologie , Maladie de Behçet/traitement médicamenteux , Cyclophosphamide/administration et posologie , Immunosuppresseurs/administration et posologie , Vascularite rétinienne/traitement médicamenteux , Uvéite antérieure/traitement médicamenteux , Uvéite postérieure/traitement médicamenteux , Maladie de Behçet/complications , Maladie de Behçet/diagnostic , Résistance aux substances , Association de médicaments , Humains , Études longitudinales , Prednisolone/administration et posologie , Pharmacothérapie administrée en bolus , Récupération fonctionnelle , Enregistrements , Vascularite rétinienne/diagnostic , Vascularite rétinienne/étiologie , Vascularite rétinienne/physiopathologie , Facteurs temps , Résultat thérapeutique , Uvéite antérieure/diagnostic , Uvéite antérieure/étiologie , Uvéite antérieure/physiopathologie , Uvéite postérieure/diagnostic , Uvéite postérieure/étiologie , Uvéite postérieure/physiopathologie , Acuité visuelle/effets des médicaments et des substances chimiquesRÉSUMÉ
BACKGROUND: Ocular manifestations of Behcet's disease (BD) need aggressive treatment to prevent severe loss of vision or blindness. Cytotoxic drugs are the main therapeutic agents and the first line treatment. Methotrexate is the least toxic, used mainly for posterior uveitis. We present here the outcome of eye lesions with methotrexate and prednisolone, in a longitudinal study of up to 15 years, on 682 patients (5447 eye-years of follow-up). PATIENTS AND METHODS: Methotrexate was started at 7.5-15 mg/week. Prednisolone was added at 0.5 mg/kg/daily, then adjusted as needed. INCLUSION CRITERIA: (i) fulfilling the International Criteria for Behcet's Disease; and (ii) having active posterior uveitis (PU). Visual acuity (VA) was calculated on a scale of 10. Activity indexes were calculated for PU and retinal vasculitis (RV) for each eye. Total Inflammatory Activity Index (TIAI) demonstrating the inflammatory index of both eyes of the patient, and Total Adjusted Disease Activity Index (TADAI) showing both TIAI + VA were also calculated. RESULTS: Overall results: the mean VA improvement was 0.4 (P < 001), PU 1.2 (P < 0.001) and RV 0.6 (P < 0.001). VA improved in 46.5%, PU in 75.4%, and RV in 53.7% of eyes. TIAI improved in 74% of patients and TADAI in 69.4%. VA was aggravated in 37.2%, PU in 11.1%, and RV in 30.3% of eyes. TIAI was aggravated in 17.4% and TADAI in 21.6% of the patients. The remaining kept their baseline values. CONCLUSION: All parameters improved, PU better than RV. Improvement of VA was the least, mainly due to secondary cataracts.
Sujet(s)
Anti-inflammatoires/usage thérapeutique , Maladie de Behçet/traitement médicamenteux , Méthotrexate/usage thérapeutique , Vascularite rétinienne/traitement médicamenteux , Uvéite antérieure/traitement médicamenteux , Uvéite postérieure/traitement médicamenteux , Acuité visuelle/effets des médicaments et des substances chimiques , Anti-inflammatoires/effets indésirables , Maladie de Behçet/complications , Maladie de Behçet/diagnostic , Opacification de la capsule postérieure/étiologie , Association de médicaments , Glucocorticoïdes/usage thérapeutique , Humains , Études longitudinales , Méthotrexate/effets indésirables , Prednisolone/usage thérapeutique , Récupération fonctionnelle , Enregistrements , Vascularite rétinienne/diagnostic , Vascularite rétinienne/étiologie , Vascularite rétinienne/physiopathologie , Indice de gravité de la maladie , Facteurs temps , Résultat thérapeutique , Uvéite antérieure/diagnostic , Uvéite antérieure/étiologie , Uvéite antérieure/physiopathologie , Uvéite postérieure/diagnostic , Uvéite postérieure/étiologie , Uvéite postérieure/physiopathologieRÉSUMÉ
BACKGROUND: The only diagnostic test that currently exists for Behcet's disease (BD) is the pathergy test. A positive pathergy test (PPT) is an important component of many of the 16 sets of classification/diagnosis criteria used to diagnose BD. The aim of this study was to determine the importance of a PTT in the performance of the diagnosis/classification criteria for BD. PATIENTS AND METHODS: All patients listed in the BD registry of the Rheumatology Research Center, Tehran (6,727) and 4,648 BD controls were enrolled in the study. The diagnosis was clinical when no other diagnosis could explain the patient's manifestations. The criteria were tested with and without PPT results. Sensitivity, specificity, and accuracy were calculated. RESULTS: Without PPT, all sets of criteria lost sensitivity, gained specificity, and lost accuracy, with the exception of the Cheng-Zhang criteria. The largest loss in sensitivity was for the Hubault-Hamza (35 %) and Dilsen (17.3 %) criteria; the least was for the Curth (1.9 %) and ICBD (6.5 %) criteria. The largest gain on specificity was for the Dilsen (4.7 %) and Curth (3.1 %) criteria; the least was for the Japan (0.1 %) and Japan revised (0.1 %) criteria. The greatest loss in accuracy was for the Hubault-Hamza (20.4 %) and Dilsen revised (9.3 %) criteria; the least was for the ICBD (3.6 %), while Curth gained 0.3 %. CONCLUSION: Without PPT as a criterion for the diagnosis of BD, the sensitivity and accuracy of the sets of classification/diagnosis criteria decrease, while the specificity improves.
Sujet(s)
Maladie de Behçet/diagnostic , Erreurs de diagnostic/prévention et contrôle , Hypersensibilité immédiate/étiologie , Tests cutanés/méthodes , Peau/anatomopathologie , Maladie de Behçet/classification , Maladie de Behçet/immunologie , Évolution de la maladie , Humains , Hypersensibilité immédiate/immunologie , Valeur prédictive des tests , Enregistrements , Reproductibilité des résultats , Peau/physiopathologieRÉSUMÉ
AIM: In Behcet's disease (BD), it is customary to believe that men are more affected than women, major organs are more involved in men, and they have worse outcomes. The male-to-female ratio is reported from 5.37 to 1 (Egypt), to 0.38 to 1 (US). If in the majority of reports BD was seen more frequently in men, in some others it was more frequent in women. The aim of this study was to examine a large cohort of patients, in whom manifestations were gender related, and to examine the strength of associations and their clinical relevance. PATIENTS AND METHODS: All patients of the BD registry, Rheumatology Research Center, Tehran University of Medical Sciences, entered the study (6702 patients). The percentage of 95 items was calculated in both genders (with their 95% confidence intervals), and were compared together by the chi-squared test. Odds ratio (OR) and relative risk (RR) were also calculated. RESULTS: Forty-three out of 95 items were gender-related (29 for males, 14 for females) with a statistically significant difference by chi-squared. Significant OR (confidence interval not reaching 1) was found for 79 items. However, clinically significant OR (2 or more for men and 0.5 or less for women) showed an association only with 16 items; five with females and 11 with males. The most important was vascular involvement. CONCLUSION: No strong association (OR of 2 or more) was found between the male gender and major organ involvement, except for vascular lesions.
Sujet(s)
Maladie de Behçet/complications , Maladie de Behçet/diagnostic , Maladie de Behçet/épidémiologie , Loi du khi-deux , Femelle , Humains , Iran/épidémiologie , Mâle , Odds ratio , Pronostic , Enregistrements , Appréciation des risques , Facteurs de risque , Répartition par sexe , Facteurs sexuelsRÉSUMÉ
BACKGROUND: Ocular lesions, the main morbidity of Behcet's disease (BD), are the most difficult to treat. The aim of this study was to evaluate the efficacy of rituximab. METHODS: Inclusion criteria were retinal vasculitis and edema, resistant to cytotoxic drugs. Twenty patients were randomized to a rituximab group (RG) or cytotoxic combination therapy group (CCTG). Rituximab was given in two 1000-mg courses (15-day interval). Subjects received methotrexate (15 mg/weekly) with prednisolone (0.5 mg/kg per day). The CCTG received pulse cyclophosphamide (1000 mg/monthly), azathioprine (2-3 mg/kg per day) and prednisolone (0.5 mg/kg per day). The primary endpoint was the overall state of patients' eyes and the Total Adjusted Disease Activity Index (TADAI). Secondary endpoints were: visual acuity (VA), posterior uveitis (PU), and retinal vasculitis (RV). The baseline data were compared at 6 months by paired sample t-test and analysis of variance. RESULTS: TADAI improved significantly in the RG (t = 3.340, P = 0.009), but not in the CCTG (t = 2.241, P = 0.052). For secondary endpoints (RG/CCTG), the mean VA improved in two patients versus three (2/3), remained unchanged in 1/1, and worsened in 7/6 patients. The mean PU improved significantly in the RG (t = 3.943, P = 0.001), not in the CCTG (t = 2.371, P = 0.028). RV improved, but not statistically (t = 2.027, P = 0.057 vs. t = 1.045, P = 0.31). Edema of retina, disc and macula improved significantly in both, but much better for the RG (t = 2.781, P = 0.012 vs. t = 2.707, P = 0.014). CONCLUSION: Rituximab was efficient in severe ocular manifestations of BD, TADAI improved significantly after 6 months with rituximab, but not with CCT.
Sujet(s)
Anticorps monoclonaux d'origine murine/usage thérapeutique , Maladie de Behçet/complications , Immunosuppresseurs/usage thérapeutique , Oedème papillaire/traitement médicamenteux , Vascularite rétinienne/traitement médicamenteux , Uvéite antérieure/traitement médicamenteux , Uvéite postérieure/traitement médicamenteux , Adolescent , Adulte , Anticorps monoclonaux d'origine murine/effets indésirables , Azathioprine/usage thérapeutique , Cyclophosphamide/usage thérapeutique , Association de médicaments , Femelle , Humains , Immunosuppresseurs/effets indésirables , Iran , Mâle , Méthotrexate/usage thérapeutique , Adulte d'âge moyen , Oedème papillaire/étiologie , Oedème papillaire/physiopathologie , Projets pilotes , Prednisolone/usage thérapeutique , Vascularite rétinienne/étiologie , Vascularite rétinienne/physiopathologie , Rituximab , Indice de gravité de la maladie , Méthode en simple aveugle , Facteurs temps , Résultat thérapeutique , Uvéite antérieure/étiologie , Uvéite antérieure/physiopathologie , Uvéite postérieure/étiologie , Uvéite postérieure/physiopathologie , Acuité visuelle/effets des médicaments et des substances chimiques , Jeune adulteRÉSUMÉ
INTRODUCTION: Behcet's Disease (BD) is classified as a vasculitis, and progresses via attacks and remissions. BD is mainly seen around the Silk Road. The picture varies in different reports. For clinical descriptions, the data from the international cohort of patients (27 countries), will be used. CLINICAL MANIFESTATIONS: Mucous membrane manifestations were oral aphthosis seen in 98.1%, and genital aphthosis in 76.9% of patients. Skin manifestations were seen in 71.9% (pseudofolliculitis in 53.6% and erythema nodosum in 33.6%). Ocular manifestations were seen in 53.7% (anterior uveitis 38.8%, posterior uveitis 36.9%, retinal vasculitis 23.5%). Joint manifestations were seen in 50.5% (arthralgia, monoarthritis, oligo/polyarthritis, ankylosing spondylitis). Neurological manifestations were seen in 15.5% of patients (central 11.5%, peripheral 4.4%). Gastrointestinal manifestations were seen in 6.3% of patients. Vascular involvement was seen in 18.2% of patients and arterial involvement in 3% (thrombosis, aneurysm, pulse weakness). Deep vein thrombosis was seen in 8%, large vein thrombosis in 6.5%, and superficial phlebitis in 5.8%. Orchitis and epididymitis were seen in 7.2%. Pathergy test was positive in 49.3% and HLA-B51 in 49.1% of patients. DIAGNOSIS: Diagnosis is based on clinical manifestations. The International Criteria for Behcet's Disease (ICBD) may be helpful. TREATMENT: The first line treatment is colchicine (1 mg daily) for mucocutaneous manifestations, non-steroidal anti-inflammatory drugs for joint manifestations, anticoagulation for vascular thrombosis, and cytotoxic drugs for ocular and brain manifestations. If incomplete response or resistance occurs, therapeutic escalation is worthwhile. CONCLUSION: Behcet's disease is a systemic disease characterized by mucocutaneous, ocular, vascular and neurologic manifestations, progressing by attacks and remissions.
Sujet(s)
Maladie de Behçet/diagnostic , Maladie de Behçet/thérapie , Maladie de Behçet/complications , Études de cohortes , Femelle , Humains , Coopération internationale , Mâle , Types de pratiques des médecinsRÉSUMÉ
AIM: To evaluate the performance of the new International Criteria for Behçet's Disease (ICBD) in Iran. The ICBD was created in 2006 to replace the International Study Group (ISG) criteria (created in 1990). In this study, 14 existing diagnosis/classification criteria (Curth, Hewitt, Mason and Barnes, Japan original, Hubault and Hamza, O'Duffy, Cheng and Zhang, Dilsen, Japan revised, International Study Group, Iran traditional, Iran Classification Tree, revised Dilsen, Korea), were evaluated and compared to ICBD by calculating their sensitivity, specificity and accuracy. METHODS: All patients from the Behçet's Disease registry (6128) and controls (3400), up to January 2008, entered the study. The diagnosis was clinical and not by any of the above-mentioned criteria. Sensitivity, specificity, accuracy (percent agreement), and 95% confidence interval were calculated. The performance of ICBD and ISG were compared by the McNemar test. RESULTS: The sensitivity was 98.2% for ICBD and 78.1% for ISG (P < 0.0001). The specificity was 95.6% for ICBD and 98.4% for ISG (P < 0.0001). The accuracy was 97.3% for ICBD and 85.5% for ISG (P < 0.0001). DISCUSSION: In Iranian patients, ICBD has 20.1% higher sensitivity and 11.8% higher accuracy than ISG, while the specificity was only 2.8% lower. ICBD was better optimized than ISG (difference between sensitivity and specificity 2.6% vs 20.3%). CONCLUSION: ICBD has by far better performance than ISG in Iran. The difference is even more prominent in Iranian patients than in the cohort of the international patients upon whom the criteria were created.
Sujet(s)
Maladie de Behçet/diagnostic , Indicateurs d'état de santé , Adolescent , Adulte , Âge de début , Sujet âgé , Asiatiques , Maladie de Behçet/complications , Maladie de Behçet/ethnologie , Études cas-témoins , Loi du khi-deux , Femelle , Humains , Iran/épidémiologie , Fonctions de vraisemblance , Mâle , Adulte d'âge moyen , Odds ratio , Valeur prédictive des tests , Courbe ROC , Enregistrements , Reproductibilité des résultats , Sensibilité et spécificité , Jeune adulteRÉSUMÉ
Behcet's disease (BD) is classified among vasculitides. There are actually five nationwide surveys of BD: Iran, Japan, China, Korea, and Germany. Among case series, four are on more than 200 cases (Turkey, Morocco, Tunisia, and UK). BD was classically seen around the Silk Route. Now, it is seen everywhere. The male to female ratios were, respectively (in nationwide surveys), 1.19, 0.98, 1.34, 0.63, and 1.40 to 1. The mean age at onset was 26.2, 35.7, 33.8, 29, and 26 years. Major manifestations were seen, respectively, in nationwide surveys: mucous membrane (oral aphthosis in 97%, 98%, 98%, 99%, and 98%; genital aphthosis in 65%, 73%, 76%, 83%, and 64%); skin manifestations (pseudo-folliculitis in 57%, N/A, 31%, N/A, and 62%; erythema nodosum in 22%, N/A, 38%, N/A, and 42%; ocular manifestations in 55%, 69%, 35%, 51%, and 53%). Minor manifestations were seen, respectively, in nationwide surveys: joint manifestations in 33%, 57%, 30%, 38%, and 53%; neurological manifestations in 9%, 11%, 6.5%, 4.6%, and 11%; gastrointestinal manifestations in 7%, 15.5%, 9%, 7.3%, and 12%; vascular involvement in 8.9%, 8.9%, 7.7%, 1.8%, and 13%; pulmonary manifestations in 0.3%, N/A, 2.2%, N/A, and 3.6%; cardiac manifestations in 0.5%, N/A, 4%, N/A, and 3.2%. Laboratory tests are not useful except the pathergy test, which was positive in 54%, 44%, N/A, 40%, and 34% of cases. ESR was normal in many patients. Diagnosis is based upon clinical manifestations. The International Criteria for Behcet's Disease (ICBD, 2006) may be of help, having a sensitivity of 98.2% and a specificity of 95.6% in Iranian patients.
Sujet(s)
Maladie de Behçet , Enquêtes de santé , Adulte , Maladie de Behçet/complications , Maladie de Behçet/diagnostic , Maladie de Behçet/épidémiologie , Chine , Femelle , Allemagne , Antigènes HLA-B/immunologie , Antigène HLA-B51 , Humains , Iran , Japon , Corée , MâleRÉSUMÉ
OBJECTIVE: To identify the clinical picture of Behcet's disease in a large cohort of patients (6500) in Iran, over a period of 35 years, and compare them with other large series from around the world. METHODS: Patients with Behcet's disease from all over Iran were seen in the Behcet's Disease Research Unit by a multidisciplinary team (rheumatologists, dermatologists, and ophthalmologists). Diagnosis was based on 'expert opinion'. Data were collected on a standardized data sheet (105 items), and stored in an electronic database. Data were updated at each follow-up. RESULTS: Male to female ratio was 1.22 : .00. The mean age at onset was 26 years ± 11.3. The frequency of symptoms were: oral aphthosis 97.3%, genital aphthosis 64.6%, skin manifestations 64.9% (pseudofolliculitis 54.5%, erythema nodosum 22.5%, other lesions 7%), pathergy phenomenon 52.5%, ophthalmologic manifes-tations 56.8% (anterior uveitis 41.2%, posterior uveitis 44.9%, retinal vasculitis 32.1%), joint manifestations 37.4% (arthralgia 17.2%, monoarticular arthritis 7.6%, oligoarthritis 16.8%, ankylosing spondylitis 2%), neurological manifestations 3.8% (central manifestations 3.5%, mononeuritis multiplex 0.3%), gastrointestinal manifestations 7.4%, vascular involvement 8.3% (phlebitis 5.7%, superficial phlebitis 2.2%, large vein thrombosis 1.1%, arterial thrombosis 0.154%, aneurysm 0.5%), epididymitis 4.7%, cardiac involvement 0.6%, and pulmonary involvement 0.9%. Sedimentation rate was normal in 46.5% of patients. Abnormal urine sediment was detected in 12.2%. HLA-B5 was present in 53.3% and HLA-B51 in 47.9% of patients. CONCLUSION: Behcet's disease is mainly seen in young people. The most frequent symptoms are mucocutaneous, ocular and joint manifestations. Comparison with large series did not show major differences.